



# FINAL PROGRAM VACCINES-2025

3rd International Conference on

### Vaccines Research and Development

May 26, 2025 | Amsterdam, Netherlands

### Day 1 | May 26, 2025

Conference Chair		Barry T. Rouse, University of Tennessee, USA
Conference Co-Chair		W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA
		Plenary Presentations
09:00 - 09:40	P	<b>Title:</b> A Platform of Fourth Generation Adenoviral Vectors for Vaccines and Applications Beyond
		Uwe D. Staerz, Chief Scientific Officer Greffex, USA
09:40 - 10:20	P	Title: Management of Viral Immunopathological Diseases
		Barry T. Rouse, University of Tennessee, USA
10:20 - 11:00	P	<b>Title:</b> Unraveling Vaccine Hesitancy: A Cross-Disciplinary Approach to Identifying Barriers and Evolving Interdisciplinary Interventions
10.20 - 11.00		Gulzar H. Shah, Georgia Southern University, USA
11:00 - 11:15		Refreshment Break
11:15 - 11:55	P	<b>Title:</b> Inadvertent Outcomes of using Monkey Kidney Cells to Produce Polio Vaccines
11.13 - 11.33		W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA
	P	<b>Title:</b> Lessons Learnt from 3 Decades of HIV and Cancer Vaccines for a Covid Vaccine
11:55 - 12:35		Angus G. Dalgleish, St. George's University of London, England
12:35 - 13:15	P	<b>Title:</b> Implementing Strategic Plasma Resource Self-Sufficiency Through Unpaid Plasma Donations on the Global Plasma Market
		Jean Mercier Ythier, University Paris-Panthéon-Assas, France
13:15 - 14:15		Group Photo & Lunch Break
14:15 - 14:55	P	Title: VLP Polio Vaccine-The Ultimate Solution for Post Eradication World
		Chunlin Xin, Vice President at CanSino Biologics, China
14:55 - 15:35	P	Title: SYN023 mAb Cocktail for Rabies Prophylaxis
		Eric Tsao, CEO at Synermore Biologics Co., Ltd., China

Title: The Development of a Novel Broad-Spectrum Influenza Polypeptide Vaccin Based on Multi-EpitopeTandem Sequences    Rongbao Gao, National Institute for Viral Disease Control and Prevention, China			
Title: Advancing the Efficacy of Vaccine with mRNA Technology  Yujian Zhang, CEO at Belem Therapeutics, USA  Title: Cellular Energy Support: An Alternative to Vaccination in the Prevention of Infectious Diseases  W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA  Keynote Presentations  Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus	15:35 - 16:15	P	the Service of Global Health  Merel F.M. Langelaar, Director - Biomedical Primate Research Centre,
Title: Cellular Energy Support: An Alternative to Vaccination in the Prevention of Infectious Diseases  17:10 - 17:50 P  W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA  Keynote Presentations  Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Scrum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus	16:15 - 16:30		Refreshment Break
Title: Cellular Energy Support: An Alternative to Vaccination in the Prevention of Infectious Diseases  W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA  Keynote Presentations  Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Scrum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus	16:30 - 17:10		Title: Advancing the Efficacy of Vaccine with mRNA Technology
of Infectious Diseases  W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA  Keynote Presentations  Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus		P	Yujian Zhang, CEO at Belem Therapeutics, USA
W. John Martin, Medical Director - Institute of Progressive Medicine, South Pasadena, CA, USA  Keynote Presentations  Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic  Based on Multi-EpitopeTandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus	17:10 - 17:50	ъ.	The state of the s
Title: There will be Another Nasty Virus; How will we be Prepared?  Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus		P	
Title: The Development of a Novel Broad-Spectrum Influenza Polypeptide Vaccin Based on Multi-Epitope Tandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus			Keynote Presentations
Title: The Development of a Novel Broad-Spectrum Influenza Polypeptide Vaccin Based on Multi-EpitopeTandem Sequences  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus			Title: There will be Another Nasty Virus; How will we be Prepared?
18:20 - 18:50 K  Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02	17:50 - 18:20	K	Stef Stienstra, NATO Joint CBRN Defence Centre of Excellence, Czech Republic
Rongbao Gao, National Institute for Viral Disease Control and Prevention, China  Title: Future Pandemic Response: Strengthening Vaccine R&D for Global Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02		K	<b>Title:</b> The Development of a Novel Broad-Spectrum Influenza Polypeptide Vaccine Based on Multi-EpitopeTandem Sequences
Preparedness  Salome Magalhaes, University College London, UK  Poster Presentations  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02	18:20 - 18:50		Rongbao Gao, National Institute for Viral Disease Control and Prevention, China
POSTER P01  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02	18:50 - 19:20		
POSTER P01  Title: Safety and Efficacy of RCP Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02		K	Salome Magalhaes, University College London, UK
POSTER P01  Compared to Sinopharm BBIBP: A phase III, Non-Inferiority Trial  Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02			Poster Presentations
Mohammad Hossein Fallah Mehrabadi, Razi Vaccine and Serum Research Institute, Iran  Title: The Challenge Efficacy Study of Bivalent Genotypes I and VII Inactivated Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02	POSTER	P01	
Vaccines Against Circulating Virulent Newcastle Disease Virus  POSTER P02			· · · · · · · · · · · · · · · · · · ·
	POSTER	P02	• • • • • • • • • • • • • • • • • • • •
			Mohammad Abdoshah, Razi Vaccine and Serum Research Institute, Iran

		Video Presentations
VIDEO	V01	<b>Title:</b> From Vaccination to Viral Infection: The Role of CLEC5A in Shaping Immune Responses
	V U 1	Juliana Gil Melgaco, Oswaldo Cruz Foundation, Brazil
VIDEO	V02	Title: Tecnological Advances in Quality Control of Messenger RNA
		Renata Maria dos Santos, Bio-Manguinhos, Brazil

### **End of the Conference**

### UPCOMING CONFERENCE VACCINES-2026

## 4<sup>th</sup> International Conference on Vaccines Research and Development

**APRIL 13-15, 2026 | PARIS, FRANCE** 

